Article
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Pharmacogenetics and genomics - 1 Feb 2018
Chong Huey Yi, Lim Yi Heng, Prawjaeng Juthamas, Tassaneeyakul Wichittra, Mohamed Zahurin, Chaiyakunapruk Nathorn
Abstract excerpt
OBJECTIVE: Studies found a strong association between allopurinol-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and the HLA-B*58:01 allele. HLA-B*58:01 screening-guided therapy may mitigate the risk of allopurinol-induced SJS/TEN. This study aimed to evaluate the cost-effectiveness of HLA-B*58:01 screening before allopurinol therapy initiation compared with the current practice of no...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.